免疫性血小板减少症

最后审阅: 28 八月 2022
最后更新: 01 三月 2019

小结

定义

病史和体格检查

关键诊断因素

  • 存在的危险因素
  • 出血
  • 无全身症状
  • 无药物诱导的血小板减少症
  • 无脾肿大或肝肿大
  • 无淋巴结肿大
更多 关键诊断因素

危险因素

  • 育龄期女性
  • 年龄<10 岁或>65 岁
更多 危险因素

诊断性检查

首要检查

  • 全血细胞计数和外周血涂片
更多 首要检查

需考虑的检查

  • HIV 血清学
  • 幽门螺杆菌呼气试验和粪便抗原检查
  • 丙型肝炎血清学检查
  • 甲状腺功能检测
  • 定量免疫球蛋白
  • 骨髓活检/穿刺
  • 妊娠试验
更多 需考虑的检查

治疗流程

初步治疗

所有患者(儿童或成人):存在危及生命或器官的出血

急症处理

新确诊儿童

新确诊成人(妊娠或非妊娠)

持续性治疗

儿童:持续性或慢性疾病

非妊娠成人:持续性或慢性疾病

妊娠:持续性或慢性疾病

撰稿人

作者

Marie Scully, MD, MRCP, FRCPath

Consultant Haematologist

University College London Hospitals

London

UK

利益声明

MS has received honoraria from Novartis. MS is the author of a paper cited in this topic.

鸣谢

Dr Marie Scully would like to gratefully acknowledge Professor Francesco Rodeghiero and Dr Marco Ruggeri, previous contributors to this topic.

利益声明

FR received fees for speaking and has been reimbursed by GSK and Amgen, the manufacturer of eltrombopag and romiplostim, for attending several conferences, and also received fees for consulting from GSK and Shionogi. FR and MR are authors of a number of references cited in this topic.

同行评议者

Keith McCrae, MD

Professor

Director of Benign Hematology

Cleveland Clinic

Cleveland

OH

利益声明

KM declares that he has no competing interests.

Sandeep Kumar Rajan, MD

Assistant Professor

Division of Oncology-Hematology

Department of Internal Medicine

University of Nebraska Medical Center

Omaha

NE

利益声明

SKR declares that he has no competing interests.

内容使用需遵循免责声明